Outbrain readies for Nasdaq IPO with senior appointment
– The Israeli content recommendation company has appointed former Check Point exec Ronen Koehler as head of staff. Outbrain is bolstering its management structure ahead of its planned IPO on Wall Street. More...
Outbrain files for Nasdaq IPO at $1 billion company value – report
– The Israeli content recommendation company filed confidentially, the “Wall Street Journal” reports. Outbrain Inc. has filed confidentially with the US Securities and Exchange Commission More...
Drug developer NeuroDerm to begin Nasdaq IPO
– The Israeli Parkinson’s disease treatment developer is seeking $58-72 million at a company value of $290 million. – Rehovot-based NeuroDerm, which has developed a transdermal drug More...
VBL Therapeutics raises $40 million in revived Nasdaq IPO
– After the fiasco of the failed IPO in August, the drug development company scaled down the offering. VBL Therapeutics has raised $40 million at a company value of $120 million in a revived IPO on Nasdaq. More...
CyberArk Software nearly doubles after Nasdaq IPO
– The Israel based cyber security company has a market cap of $881 million. – Israeli cyber security firm CyberArk has made a huge impact with its NASDAQ IPO, which was held on the eve of More...
Foamix sets terms for $71 million Nasdaq IPO
– Foamix integrates its foam technology with existing drugs used to treat skin diseases like acne. – Foamix, which develops foam-based drugs, today revised its prospectus for its upcoming IPO More...
ReWalk Robotics sets terms for $50 million Nasdaq IPO
– The company plans the offering in the second week of September. – – ReWalk Robotics has set terms for its Nasdaq IPO. The Israel-based company recently changed its name from Argo Medical More...
Israeli Macrocure raises $54 million in Nasdaq IPO
– The advanced cell therapy for chronic wound therapy company pricing of the shares at $10 was well below the $13-15 range that the company had planned. Regenerative medicine developer Macrocure Ltd. has More...
VBL Therapeutics prices Nasdaq IPO
– The clinical stage biotech company is selling 5.4 million ordinary shares at $12 each. Clinical-stage biotech company VBL Therapeutics has announced the pricing of its Nasdaq IPO. The company is selling More...
MacroCure Is The latest Israeli Biotech Firm to Go public In The US
– Startup nation continues to shine in the field of biotechnology while shunning Israeli exchanges. – – Israeli biotech firm MacroCure has announced plans to hold an initial public offering More...